Trials / Completed
CompletedNCT00478179
Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia
A Randomized, Double-Blind, Placebo Controlled, Two-Way Cross-Over Study of Analgesic Efficacy of Bupivacaine Transdermal Therapeutic System in Patients With Post-Herpetic Neuralgia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Durect · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
Neuropathic pain is caused by a virus commonly associated with chicken pox. This virus may become dormant in the nervous system and later reactivate causing herpes zoster, also known as "shingles". Post-herpetic neuralgia (PHN) is a persistent pain in the area of healed skin lesions. This study will test the safety and efficacy of treating PHN patients with the analgesic patch, Bupivacaine TTS (Eladur™).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Transdermal/Patch (Bupivacaine TTS [Eladur™]) |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2007-12-01
- Completion
- 2007-12-01
- First posted
- 2007-05-24
- Last updated
- 2009-09-11
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00478179. Inclusion in this directory is not an endorsement.